June 16th 2025
The company’s successful completion of facility and equipment qualifications gives it another biologics manufacturing option alongside its United States campus in Morgan Hill, Calif.
An Alternative Platform for Rapid Production of Effective Subunit Vaccines
Adjuvant activity can be greatly improved by appropriate formulation of cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs).
Biopharmaceutical Facility Cleaning Validation Using the Total Organic Carbon Test
Case studies show TOC is effective for cleaning validation.
A Study of Leachables for Biopharmaceutical Formulations Stored in Rubber-Stoppered Glass Vials
A systematic approach facilitates formulation component selection.
Xcellerex and Humacyte to Develop Single-Use Manufacturing Technology to Grow Vascular Grafts
March 10th 2010Humacyte, Inc. (Research Triangle Park, NC) and Xcellerex, Inc. (Marlborough, MA) have entered into an initial strategic collaboration for Xcellerex to develop a manufacturing process that will enable the production of Humacyte?s lead regenerative medicine product using Xcellerex?s XDR single-use bioreactor system in its FlexFactory.